ANDA 77022, held by Epic Pharma LLC. Cilostazol.
As of Nov 16, 2026, ANDA 77022 (Cilostazol), held by Epic Pharma LLC, was first approved by FDA on Nov 23, 2004, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 2004 | Original application | Approved |
| Cilostazol100MG · tablet;oral | Cilostazol | Rx |
| Cilostazol50MG · tablet;oral | Cilostazol | Rx |
| Nov 18, 2020 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 21, 2017 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 6, 2010 | Supplement 7Labeling | Approved | None posted |
| May 27, 2010 | Supplement 5Labeling | Approved | None posted |
| Feb 14, 2008 | Supplement 3Labeling | Approved | None posted |
| Feb 14, 2006 | Supplement 2Labeling | Approved | None posted |
| Nov 23, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters